Hospitalisations dues aux effets indésirables des médicaments : résultats d'une étude nationale [cité 23 nov 2016] Disponible sur: http://social-? sante.gouv.fr Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients, BMJ. 3 juill, vol.329, issue.7456, pp.15-24, 2004. ,
Disponible sur: http://www.atih.sante.fr/sites Analysis of adverse drug reactions for preventability, 2015. ,
Facteurs à prendre en considération pour la gestion des interactions médicamenteuses en pratique clinique. Presse Médicale654?64. 8. FDA, Drug Development and Drug Interactions, www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugIntera ctionsLabeling/ucm080499.htm 9. Guideline on the investigation of drug interactions -? [cité 24 nov 2016]. Disponible sur, 2008. ,
DOI : 10.1016/j.lpm.2007.08.012
Changes in plasma protein binding have little clinical relevance, Clinical Pharmacology & Therapeutics, vol.71, issue.3, pp.115-136, 2002. ,
DOI : 10.1067/mcp.2002.121829
When is Protein Binding Important?*, Journal of Pharmaceutical Sciences, vol.102, issue.9, pp.3458-67, 2013. ,
DOI : 10.1002/jps.23559
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics, Science, vol.286, issue.5439, pp.487-91, 1999. ,
DOI : 10.1126/science.286.5439.487
la pharmacogénétique ou la promesse d'une médecine personnalisée, Ann Biol Clin, vol.62, pp.499-511, 2004. ,
Inhibition and Induction of Cytochrome P450 and the Clinical Implications, Clinical Pharmacokinetics, vol.35, issue.5, pp.361-90, 1998. ,
DOI : 10.2165/00003088-199835050-00003
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib, Journal of Clinical Oncology, vol.28, issue.14, pp.2381-2389, 2010. ,
DOI : 10.1200/JCO.2009.26.3087
The potential for drug interactions, Annals of Emergency Medicine, vol.10, issue.12, pp.627-630, 1981. ,
DOI : 10.1016/S0196-0644(81)80085-6
Drug???drug interactions in oncology: Why are they important and can they be minimized?, Critical Reviews in Oncology/Hematology, vol.55, issue.2, pp.117-159, 2005. ,
DOI : 10.1016/j.critrevonc.2005.03.007
Potential health risks of complementary alternative medicines in cancer patients, British Journal of Cancer, vol.90, issue.2, pp.408-421, 2004. ,
DOI : 10.1038/sj.bjc.6601560
Drug interactions in oncology: how common are they?, Annals of Oncology, vol.20, issue.12, 2009. ,
DOI : 10.1093/annonc/mdp369
Adverse Drug Reactions and Drug Interactions as Causes of Hospital Admission in Oncology, Journal of Pain and Symptom Management, vol.42, issue.3, pp.342-53, 2011. ,
DOI : 10.1016/j.jpainsymman.2010.11.014
Drug???drug interactions with tyrosine-kinase inhibitors: a clinical perspective, The Lancet Oncology, vol.15, issue.8, pp.315-326, 2014. ,
DOI : 10.1016/S1470-2045(13)70579-5
Enzyme-Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors, Journal of Pharmaceutical Sciences, vol.103, issue.12, pp.3810-3843, 2014. ,
DOI : 10.1002/jps.24113
Oral targeted therapies: managing drug interactions, enhancing adherence and optimizing medication safety in lymphoma patients, Expert Review of Anticancer Therapy, vol.15, issue.4, pp.453-64, 2015. ,
DOI : 10.1586/14737140.2015.1014807
Drug? drug interactions with imatinib: An observational study, ) [Internet]. oct 2016, 2016. ,
Review of therapeutic drug monitoring of anticancer drugs part two ??? Targeted therapies, European Journal of Cancer, vol.50, issue.12, pp.2020-2056, 2014. ,
DOI : 10.1016/j.ejca.2014.04.015
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia, Blood, vol.109, issue.8, pp.3496-3505, 2007. ,
DOI : 10.1182/blood-2006-07-036012
The B-cell receptor signaling pathway as a therapeutic target in CLL, Blood, vol.120, issue.6, pp.1175-84, 2012. ,
DOI : 10.1182/blood-2012-02-362624
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma, Nature, vol.14, issue.7277, pp.88-92, 2010. ,
DOI : 10.1038/nature08638
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765, Blood, vol.117, issue.23, pp.6287-96, 2011. ,
DOI : 10.1182/blood-2011-01-328484
PI3K in lymphocyte development, differentiation and activation, Nature Reviews Immunology, vol.3, issue.4, pp.317-347, 2003. ,
DOI : 10.1038/nri1056
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy, Proceedings of the National Academy of Sciences, vol.107, issue.29, pp.13075-80, 2010. ,
DOI : 10.1073/pnas.1004594107
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia, Blood, vol.118, issue.13, pp.3603-3615, 2011. ,
DOI : 10.1182/blood-2011-05-352492
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma, Clinical Cancer Research, vol.21, issue.7, pp.1537-1579, 2015. ,
DOI : 10.1158/1078-0432.CCR-14-2034
The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-?cell disorders, Blood, vol.83, issue.6, pp.1558-1562, 1994. ,
Disponible sur: http://www.has-? sante, pp.2011-2020, 2016. ,
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up, Blood, vol.112, issue.8, pp.3322-3329, 2008. ,
DOI : 10.1182/blood-2008-04-154070
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.343, issue.26, pp.1910-1916, 2000. ,
DOI : 10.1056/NEJM200012283432602
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia, Blood, vol.94, issue.6, pp.1840-1847, 1999. ,
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis, Cancer, vol.42, issue.1, pp.198-206, 1981. ,
DOI : 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V
Disponible sur: http://www.has-? sante.fr/portail/upload/docs/application, 2016. ,
The cellular origin of mantle cell lymphoma, The International Journal of Biochemistry & Cell Biology, vol.39, issue.10, pp.1747-53, 2007. ,
DOI : 10.1016/j.biocel.2007.04.026
Mantle Cell Lymphoma: Biology, Clinical Presentation, and Therapeutic Approaches, American Society of Clinical Oncology Educational Book, vol.34 ,
DOI : 10.14694/EdBook_AM.2014.34.191
Waldenstr??m macroglobulinemia: 2015 update on diagnosis, risk stratification, and management, American Journal of Hematology, vol.71, issue.2, pp.346-54, 2015. ,
DOI : 10.1002/ajh.23922
Waldenstr??m's macroglobulinemia: a clinical perspective in the era of novel therapeutics, Annals of Oncology, vol.27, issue.2, pp.233-273, 2016. ,
DOI : 10.1093/annonc/mdv572
Ibrutinib: First Global Approval, Drugs, vol.31, issue.1, pp.263-71, 2014. ,
DOI : 10.1007/s40265-014-0178-8
Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib, Clinical Pharmacokinetics, vol.97, issue.10, pp.33-45, 2016. ,
DOI : 10.1007/s40262-015-0304-0
Population pharmacokinetic modeling of idelalisib, a novel PI3K?? inhibitor, in healthy subjects and patients with hematologic malignancies, Cancer Chemotherapy and Pharmacology, vol.37, issue.6, pp.89-98, 2016. ,
DOI : 10.1007/s00280-015-2891-8
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia, Cancer Chemotherapy and Pharmacology, vol.75, issue.5, pp.907-923, 2015. ,
DOI : 10.1007/s00280-015-2708-9
Pharmacokinetic and Pharmacodynamic Implications of P-glycoprotein Modulation, Pharmacotherapy, vol.58, issue.7, pp.778-796, 2001. ,
DOI : 10.1046/j.1432-1327.1999.00644.x
Drug???Drug Interactions Mediated Through P-Glycoprotein: Clinical Relevance and In Vitro???In Vivo Correlation Using Digoxin as a Probe Drug, Clinical Pharmacology & Therapeutics, vol.38, issue.2, pp.173-81, 2009. ,
DOI : 10.1177/0091270006292624
The role of aldehyde oxidase in drug metabolism, Expert Opinion on Drug Metabolism & Toxicology, vol.6, issue.4, pp.487-503, 2012. ,
DOI : 10.1371/journal.pone.0005348
Human Liver Aldehyde Oxidase: Inhibition by 239 Drugs, The Journal of Clinical Pharmacology, vol.185, issue.Suppl., pp.7-19, 2004. ,
DOI : 10.1177/0091270003260336
Aldehyde Oxidase: An Enzyme of Emerging Importance in Drug Discovery, Journal of Medicinal Chemistry, vol.53, issue.24, pp.8441-60, 2010. ,
DOI : 10.1021/jm100888d
In vitro selective inhibition of human UDP-glucuronosyltransferase (UGT) 1A4 by finasteride, and prediction of in vivo drug???drug interactions, Toxicology Letters, vol.232, issue.2, pp.458-65, 2015. ,
DOI : 10.1016/j.toxlet.2014.11.018
UDP-glucuronosyltransferases and clinical drug-drug interactions, Pharmacology & Therapeutics, vol.106, issue.1, pp.97-132, 2005. ,
DOI : 10.1016/j.pharmthera.2004.10.013
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia, New England Journal of Medicine, vol.371, issue.3, pp.213-236, 2014. ,
DOI : 10.1056/NEJMoa1400376
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134521
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.370, issue.11, pp.997-1007, 2014. ,
DOI : 10.1056/NEJMoa1315226
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161365
PI3K?? Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma, New England Journal of Medicine, vol.370, issue.11, pp.1008-1026, 2014. ,
DOI : 10.1056/NEJMoa1314583
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039496
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions, Blood, vol.124, issue.26, pp.3991-3996, 2014. ,
DOI : 10.1182/blood-2014-06-583294
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience, Blood, vol.128, issue.18, p.2016, 2016. ,
DOI : 10.1182/blood-2016-05-716977
Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants, Pharmacology Research & Perspectives, vol.43, issue.4, p.156, 2015. ,
DOI : 10.1002/prp2.156
Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report, Journal of Clinical Pharmacy and Therapeutics, vol.34, issue.1, pp.104-109, 2016. ,
DOI : 10.1111/jcpt.12355
Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling, Clinical Pharmacology & Therapeutics, vol.34, issue.5, pp.548-57, 2016. ,
DOI : 10.1002/cpt.419
Drug interaction between idelalisib and diazepam resulting in altered mental status and respiratory failure, Journal of Oncology Pharmacy Practice, vol.41 ,
DOI : 10.1177/1078155216653705
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.369, issue.1, pp.32-42, 2013. ,
DOI : 10.1056/NEJMoa1215637
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772525
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma, New England Journal of Medicine, vol.369, issue.6, pp.507-523, 2013. ,
DOI : 10.1056/NEJMoa1306220
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513941
Ibrutinib in Previously Treated Waldenstr??m???s Macroglobulinemia, New England Journal of Medicine, vol.372, issue.15, pp.1430-1470, 2015. ,
DOI : 10.1056/NEJMoa1501548
Effectiveness of telephone support during chemotherapy in patients with diffuse large B cell lymphoma: The Ambulatory Medical Assistance (AMA) experience, International Journal of Nursing Studies, vol.48, issue.8, pp.926-958, 2011. ,
DOI : 10.1016/j.ijnurstu.2011.01.008
Agence nationale de sécurité du médicament et des produits de santé [Internet]. [cité 26 nov 2016]. Disponible sur: http://ansm.sante.fr/Dossiers/Interactions-?medicamenteuses/Interactions-? medicamenteuses ,
Drug Interactions?Principles, Examples and Clinical Consequences, Dtsch Ärztebl Int. août, vol.109, issue.33?34, pp.546-56, 2012. ,
Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia, Current Medical Research and Opinion, vol.26, issue.12, pp.2861-2870, 2010. ,
DOI : 10.1185/03007995.2010.533648
Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs, PharmacoEconomics, vol.52, issue.5 ,
DOI : 10.2165/00019053-200725060-00004
Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia, American Journal of Hematology, vol.94, issue.6, pp.471-475, 2011. ,
DOI : 10.1002/ajh.22019